Literature DB >> 25345353

Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds.

Tomas Kalina1, Juan Flores-Montero, Quentin Lecrevisse, Carlos E Pedreira, Vincent H J van der Velden, Michaela Novakova, Ester Mejstrikova, Ondrej Hrusak, Sebastian Böttcher, Dennis Karsch, Łukasz Sędek, Amelie Trinquand, Nancy Boeckx, Joana Caetano, Vahid Asnafi, Paulo Lucio, Margarida Lima, Ana Helena Santos, Paola Bonaccorso, Alita J van der Sluijs-Gelling, Anton W Langerak, Marta Martin-Ayuso, Tomasz Szczepański, Jacques J M van Dongen, Alberto Orfao.   

Abstract

Flow cytometric immunophenotyping has become essential for accurate diagnosis, classification, and disease monitoring in hemato-oncology. The EuroFlow Consortium has established a fully standardized "all-in-one" pipeline consisting of standardized instrument settings, reagent panels, and sample preparation protocols and software for data analysis and disease classification. For its reproducible implementation, parallel development of a quality assurance (QA) program was required. Here, we report on the results of four consecutive annual rounds of the novel external QA EuroFlow program. The novel QA scheme aimed at monitoring the whole flow cytometric analysis process (cytometer setting, sample preparation, acquisition and analysis) by reading the median fluorescence intensities (MedFI) of defined lymphocytes' subsets. Each QA participant applied the predefined reagents' panel on blood cells of local healthy donors. A uniform gating strategy was applied to define lymphocyte subsets and to read MedFI values per marker. The MedFI values were compared with reference data and deviations from reference values were quantified using performance score metrics. In four annual QA rounds, we analyzed 123 blood samples from local healthy donors on 14 different instruments in 11 laboratories from nine European countries. The immunophenotype of defined cellular subsets appeared sufficiently standardized to permit unified (software) data analysis. The coefficient of variation of MedFI for 7 of 11 markers performed repeatedly below 30%, average MedFI in each QA round ranged from 86 to 125% from overall median. Calculation of performance scores was instrumental to pinpoint standardization failures and their causes. Overall, the new EuroFlow QA system for the first time allowed to quantify the technical variation that is introduced in the measurement of fluorescence intensities in a multicentric setting over an extended period of time. EuroFlow QA is a proficiency test specific for laboratories that use standardized EuroFlow protocols. It may be used to complement, but not replace, established proficiency tests.
© 2014 International Society for Advancement of Cytometry. © 2014 International Society for Advancement of Cytometry.

Entities:  

Keywords:  EuroFlow; flow cytometry; immunophenotyping; leukemia; lymphoma; quality assessment

Mesh:

Year:  2014        PMID: 25345353     DOI: 10.1002/cyto.a.22581

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  42 in total

Review 1.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

2.  Stepwise discriminant function analysis for rapid identification of acute promyelocytic leukemia from acute myeloid leukemia with multiparameter flow cytometry.

Authors:  Zhanguo Chen; Yan Li; Yongqing Tong; Qingping Gao; Xiaolu Mao; Wenjing Zhang; Zunen Xia; Chaohong Fu
Journal:  Int J Hematol       Date:  2016-01-12       Impact factor: 2.490

Review 3.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

4.  High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.

Authors:  Wanxia Li Tsai; Laura Vian; Valentina Giudice; Jacqueline Kieltyka; Christine Liu; Victoria Fonseca; Nathalia Gazaniga; Shouguo Gao; Sachiko Kajigaya; Neal S Young; Angélique Biancotto; Massimo Gadina
Journal:  J Immunol Methods       Date:  2019-11-11       Impact factor: 2.303

Review 5.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

6.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 7.  The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Authors:  Francesco Buccisano; Christopher S Hourigan; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

8.  An Integrated Workflow To Assess Technical and Biological Variability of Cell Population Frequencies in Human Peripheral Blood by Flow Cytometry.

Authors:  Julie G Burel; Yu Qian; Cecilia Lindestam Arlehamn; Daniela Weiskopf; Jose Zapardiel-Gonzalo; Randy Taplitz; Robert H Gilman; Mayuko Saito; Aruna D de Silva; Pandurangan Vijayanand; Richard H Scheuermann; Alessandro Sette; Bjoern Peters
Journal:  J Immunol       Date:  2017-01-09       Impact factor: 5.422

Review 9.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

10.  Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC.

Authors:  Bita Sahaf; Mina Pichavant; Brian H Lee; Caroline Duault; Emily M Thrash; Melanie Davila; Nicolas Fernandez; Karen Millerchip; Salah-Eddine Bentebibel; Cara Haymaker; Natalia Sigal; Diane M Del Valle; Srinika Ranasinghe; Sarah Fayle; Beatriz Sanchez-Espiridion; Jiexin Zhang; Chantale Bernatchez; Catherine J Wu; Ignacio I Wistuba; Seunghee Kim-Schulze; Sacha Gnjatic; Sean C Bendall; Minkyung Song; Magdalena Thurin; J Jack Lee; Holden T Maecker; Adeeb Rahman
Journal:  Clin Cancer Res       Date:  2021-07-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.